BIO-RAD LABORATORIES -CL B (BIO.B) Fundamental Analysis & Valuation

NYSE:BIO.B • US0905721082

Current stock price

277 USD
-1.25 (-0.45%)
Last:

This BIO.B fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. BIO.B Profitability Analysis

1.1 Basic Checks

  • BIO.B had positive earnings in the past year.
  • In the past year BIO.B had a positive cash flow from operations.
  • In multiple years BIO.B reported negative net income over the last 5 years.
  • Each year in the past 5 years BIO.B had a positive operating cash flow.
BIO.B Yearly Net Income VS EBIT VS OCF VS FCFBIO.B Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • BIO.B has a Return On Assets of 7.18%. This is amongst the best in the industry. BIO.B outperforms 87.72% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.20%, BIO.B belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 2.02%, BIO.B is doing good in the industry, outperforming 64.91% of the companies in the same industry.
  • BIO.B had an Average Return On Invested Capital over the past 3 years of 2.32%. This is significantly below the industry average of 11.38%.
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROIC 2.02%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
BIO.B Yearly ROA, ROE, ROICBIO.B Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • Looking at the Profit Margin, with a value of 29.42%, BIO.B belongs to the top of the industry, outperforming 98.25% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BIO.B has declined.
  • With a decent Operating Margin value of 10.30%, BIO.B is doing good in the industry, outperforming 71.93% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BIO.B has declined.
  • Looking at the Gross Margin, with a value of 52.01%, BIO.B is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
  • BIO.B's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
BIO.B Yearly Profit, Operating, Gross MarginsBIO.B Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIO.B Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
  • Compared to 1 year ago, BIO.B has less shares outstanding
  • Compared to 5 years ago, BIO.B has less shares outstanding
  • BIO.B has a better debt/assets ratio than last year.
BIO.B Yearly Shares OutstandingBIO.B Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
BIO.B Yearly Total Debt VS Total AssetsBIO.B Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • BIO.B has an Altman-Z score of 3.12. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.12, BIO.B is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • The Debt to FCF ratio of BIO.B is 3.21, which is a good value as it means it would take BIO.B, 3.21 years of fcf income to pay off all of its debts.
  • BIO.B's Debt to FCF ratio of 3.21 is amongst the best of the industry. BIO.B outperforms 84.21% of its industry peers.
  • BIO.B has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • BIO.B has a Debt to Equity ratio of 0.16. This is comparable to the rest of the industry: BIO.B outperforms 59.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Altman-Z 3.12
ROIC/WACC0.19
WACC10.4%
BIO.B Yearly LT Debt VS Equity VS FCFBIO.B Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 5.62 indicates that BIO.B has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 5.62, BIO.B belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
  • BIO.B has a Quick Ratio of 4.19. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BIO.B (4.19) is better than 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.19
BIO.B Yearly Current Assets VS Current LiabilitesBIO.B Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIO.B Growth Analysis

3.1 Past

  • The earnings per share for BIO.B have decreased by -3.78% in the last year.
  • BIO.B shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.19% yearly.
  • BIO.B shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
  • Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 0.29% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%

3.2 Future

  • BIO.B is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
  • The Revenue is expected to grow by 2.54% on average over the next years.
EPS Next Y4.02%
EPS Next 2Y7.43%
EPS Next 3Y6.58%
EPS Next 5Y0.58%
Revenue Next Year1.88%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIO.B Yearly Revenue VS EstimatesBIO.B Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO.B Yearly EPS VS EstimatesBIO.B Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO.B Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 27.92, which means the current valuation is very expensive for BIO.B.
  • Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 71.93% of the companies are valued more expensively.
  • BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.86, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 26.84, which means the current valuation is very expensive for BIO.B.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 70.18% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.39, BIO.B is valued a bit cheaper.
Industry RankSector Rank
PE 27.92
Fwd PE 26.84
BIO.B Price Earnings VS Forward Price EarningsBIO.B Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BIO.B's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIO.B is cheaper than 80.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.96
EV/EBITDA N/A
BIO.B Per share dataBIO.B EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of BIO.B may justify a higher PE ratio.
PEG (NY)6.94
PEG (5Y)N/A
EPS Next 2Y7.43%
EPS Next 3Y6.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIO.B Dividend Analysis

5.1 Amount

  • BIO.B does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO.B Fundamentals: All Metrics, Ratios and Statistics

BIO-RAD LABORATORIES -CL B

NYSE:BIO.B (4/7/2026, 9:19:59 PM)

277

-1.25 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners90.49%
Inst Owner Change0%
Ins Owners8.11%
Ins Owner ChangeN/A
Market Cap7.48B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target335.52 (21.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-2.04%
PT rev (3m)-7.71%
EPS NQ rev (1m)-2.47%
EPS NQ rev (3m)-28.16%
EPS NY rev (1m)-0.52%
EPS NY rev (3m)-0.62%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)-2.7%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.82%
Valuation
Industry RankSector Rank
PE 27.92
Fwd PE 26.84
P/S 2.89
P/FCF 19.96
P/OCF 14.05
P/B 1
P/tB 1.12
EV/EBITDA N/A
EPS(TTM)9.92
EY3.58%
EPS(NY)10.32
Fwd EY3.73%
FCF(TTM)13.88
FCFY5.01%
OCF(TTM)19.72
OCFY7.12%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)6.94
PEG (5Y)N/A
Graham Number248.27
Profitability
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROCE 2.65%
ROIC 2.02%
ROICexc 2.38%
ROICexgc 2.62%
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
FCFM 14.5%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.1%
Interest Coverage -5.71
Cash Conversion N/A
Profit Quality 49.3%
Current Ratio 5.62
Quick Ratio 4.19
Altman-Z 3.12
F-Score5
WACC10.4%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.02%
EPS Next 2Y7.43%
EPS Next 3Y6.58%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.88%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.1%
EBIT Next 3Y19.79%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%

BIO-RAD LABORATORIES -CL B / BIO.B Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BIO.B.


Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?

ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Fairly Valued.


Can you provide the profitability details for BIO-RAD LABORATORIES -CL B?

BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 6 / 10.


What is the financial health of BIO-RAD LABORATORIES -CL B (BIO.B) stock?

The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 8 / 10.


What is the expected EPS growth for BIO-RAD LABORATORIES -CL B (BIO.B) stock?

The Earnings per Share (EPS) of BIO-RAD LABORATORIES -CL B (BIO.B) is expected to grow by 4.02% in the next year.